ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients March 28, 2019
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib March 26, 2019
Millendo Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome March 19, 2019
ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth March 5, 2019
